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In order to realize gene-based medicine, a number of key challenges must be overcome. Construction of infrastructure capable of inte-
grating genetic and clinical information is one of those challenges. The Genomic Sequence Variation Markup Language (GSVML) and
the Health Level Seven Version 3 (HL7v3) are important electronic data exchange standards for clinical genome infrastructure, and com-
patibility between these two standards will promote the above integration. In this study, we analyzed the interface between GSVML and
HL7v3, primarily for the Clinical Genomics Domain, from a view of the GSVML, and were able to create a blueprint for a functional
interface between GSVML and HL7v3. We expect that these analytical results will help accelerate the realization of gene-based medicine.
 2006 Elsevier Inc. All rights reserved.
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In recent years, a very large amount of human genetic
information has been collected, and the amount continues
to increase daily. In particular, single nucleotide polymor-
phisms (SNPs) data for millions of nucleotide positions in
the human genome is now available, and this data may
help us ﬁnally realize the promise of ‘‘gene-based’’ medi-
cine. For example, dbSNP (build 126) [1] contain data
for over 10,000,000 SNPs, and the International HapMap
Consortium [2] has at least 1 million SNPs from 270 indi-
viduals, which will facilitate the study of direct associations
of individual SNPs with disease phenotypes. In the post-ge-
nome era, the human genomics community is turning its
attention towards understanding which genomic sequence
variations are related to human disease, and how such
genetic information could be applied in a clinical setting
[3]. True gene-based medicine, in which genetic informa-
tion could be reliably applied to disease diagnosis, phar-
macogenomics and preventive medicine, would be a
powerful tool for improving current medical issues such1532-0464/$ - see front matter  2006 Elsevier Inc. All rights reserved.
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E-mail address: hiroi@med.kobe-u.ac.jp (K. Hiroi).as quality of health care and health care cost [4–6]. Howev-
er, deﬁnitively determining the relationships between a dis-
ease, especially common diseases whose inheritance is
much more complex, including diabetes, hypertension,
asthma, common cancers, and the major neuropsychiatric
disease, and the responsible genes is very challenging
research. Both genetic information and also clinical infor-
mation is very important for these researches, and it is nec-
essary that such information be properly integrated before
detail analysis. Currently, the lack of access to controlled,
detailed clinical information, and the lack of its availability
in a structured form suitable for computational processing,
is a serious hindrance for researchers working in this ﬁeld
[7]. Therefore, Construction of clinical genome infrastruc-
ture that makes exchange and sharing of clinical data eﬃ-
cient, smooth, and reliable, is an important ﬁrst step to
solving this problem. However, as a result of the rapid
increase in the production of genetic information, a wide
variety of databases have been created (and continue to
be created) in various research laboratories, with a wide
variety of data formats. Moreover, clinical information
also has been stored in various hospitals, with various data
formats. There is thus a critical need for describing such
data in a uniﬁed, utilizable format, as well as eﬃciently
integrating this data. To respond to this need, the Genomic
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the Health Level Seven (HL7) have been put forward as
data exchange standards.
The GSVML is a sharable data exchange format
designed for exchanging genomic sequence variation data
and the corresponding annotative information. Its stan-
dardization is ongoing in the International Standardization
Organization (ISO) TC215 [9]. The GSVML have a core
concept model. It is based on the Extensible Markup Lan-
guage (XML) [10] and published the DTD and XML sche-
ma as version 1. The envisioned applications of GSVML
are in the human health domain, and GSVML is expected
to be able to integrate clinical information and other omics
information together as annotations of variation data. Spe-
ciﬁcally, the GSVML consists of three data criteria: varia-
tion data, direct annotation, and indirect annotation. The
GSVML can enhance the utilization of genomic sequence
variation data internationally by providing a sharable plat-
form for data exchange.
On the other hand, the HL7 is one of the American
National Standards Institute (ANSI) accredited Standards
Developing Organizations (SDOs) operating in the health-
care arena. The HL7 version 2.x (HL7v2.x) is the most
widely used in the world, and the HL7 version 3
(HL7v3), the latest version. The HL7v3 has the Message
Development Framework (MDF) for developing message
speciﬁcations. The MDF is a complete, fully documented,
model-based methodology and its methodology is based
on object oriented methodologies [11]. The HL7 methodol-
ogy uses the Reference Information Model (RIM) com-
posed of core six ‘‘back-bone’’ classes (Act, Participation,
Entity, Role, ActRelationship, RoleLink) and their special-
izations [12] and the HL7-speciﬁed Vocabulary Domains as
its starting point. And the HL7v3 speciﬁcation is built
around subject domains, for each of which it provides sto-
ryboard descriptions, trigger events, interaction designs,
Domain Message Information Models (D-MIM) derived
from the RIM, Reﬁned Message Information Models (R-
MIM) derived from the D-MIM, hierarchical message
descriptors (HMD) and its resulting Message Types. Final-
ly, those are encoded in XML. Based on the MDF, each
Technical Committee and Special Interest Group in
HL7v3 are contributing to the standard in its domain of
expertise. About the clinical genomics ﬁeld, the Clinical
Genomics Special Interest Group (CGSIG) [13] summa-
rized the clinical use cases for general genomic data. In
addition, the HL7 Clinical Document Architecture
(CDA), a document markup standard that speciﬁes the
structure and semantics of ‘‘clinical documents’’ for the
purpose of exchange [14,15], was developed as a part of
the HL7v3 family of standards. Within the United States,
the CDA is cited in the plans for the emerging information
exchange networks and is the basis for the planned Health
Insurance Portability Accountability Act (HIPAA)—com-
pliant claims, referrals, and authorization processes
[16,17]. The HL7 is proposed as the standard that should
be required by law. Moreover, the Institute of Medicine(IOM) reported in 2003 that standardization of the electric
health record (EHR) is necessary and indispensable for
improving the safety and quality of medical treatment
[18], and the decision regarding the functional model of
the EHR was advanced, in cooperation with the HL7 Soci-
ety. Additionally, many organizations, both within and
outside of the U.S., are actively involved in HL7v3 imple-
mentations. These include the National Cancer Institute
Center for Bioinformatics [19], the National Programme
for IT (NPfIT) in England [20], the National ICT Institute
for Healthcare (NICTIZ) in The Netherlands [21] and the
Canadian Infoway Project [22].
The integration of these two standards (GSVML and
HL7v3) would be an important ﬁrst step in the construc-
tion of a robust clinical genome infrastructure, and by this
integration, the realization of gene-based medicine in the
post-genome era would be accelerated. Therefore, in this
paper we propose a blueprint for a functional interface
between GSVML and HL7v3.
2. Method
Both standards (GSVML, HL7v3) were designed care-
fully by domain experts and incorporate model-based
methodology. Analyzing and comparing the models at a
conceptual level can be a helpful of the interface design
and the schema integration between such well-deﬁned stan-
dards [23–25]. And, the target domain of the GSVML is
the Clinical genomics domain. However, HL7v3 contains
some models in each domain. So, in order to make the
analysis simpler and clearer, we selected the GeneticLocus
Model (POCG_RM000010) [26] in the HL7v3 Clinical
Genomics Domain as a proper domain and model for com-
parison with GSVML. Because the HL7v3 Clinical
Genomics Domain has been developed as a standard mod-
el for enabling the exchange of interrelated clinical and
personalized genomic data between interested parties.
And, the GeneticLocus Model is the core model in this
domain and contains the SequenceVariation class for
describing variation information in its structure, though
this domain has three models (the GeneticLocus Model,
the GeneticLoci Model and the FamilyHistory Model) as
the Clinical Genomics Domain Information Model
(POCG_DM000020) [27] in the latest Ballot (September
2006 Ballot Package). Based on the analysis and the com-
parison, we developed the interface model with ‘‘to and
fro’’ steps. Our analysis and comparison of the models,
and development of the proposed interface between them,
was based on the following procedure:
(1) Comparison of the Scope
We compared the scope between the GSVML and the
GeneticLocus Model in order to clarify the interest
ranges of both standard models.
(2) Comparison of the Entry Point
To clarify which aspect of the model is captured, we
compared the Entry Point—i.e. ‘‘a reference point
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begin for the particular domain’’—by describing the
GSVML Entry Point in the simpliﬁed conceptual
structure of the GeneticLocus Model.
(3) Comparison of the Structure
We compared the outlined structure of GSVML with
the GeneticLocus Model. Especially, we analyzed the
relations among the concepts described in those mod-
els in order to elucidate how each standard described
concepts in the clinical genomics domain.
(4) Comparison of the Content
Based on the result of Step (3), we compared the con-
tents of the GeneticLocus Model for the GSVML’s
three data criteria, namely, variation data, direct
annotation, and indirect annotation. Moreover, we
mapped all concepts contained in GSVML to the
GeneticLocus Model in order to compare the con-
tents in more detail. Speciﬁcally, the mapping was
accomplished according to the contents of element
and attribute deﬁned in the XML schema of
GSVML. The contents (concepts) that could not be
mapped to the GeneticLocus Model usually at least
partially mapped to other domains of HL7v3. As a
result of a detailed comparison of GSVML contents
with the total HL7v3 contents, we were able to pro-
duce an overview of GSVML contents in HL7v3.
(5) Development of the Intermediate Model for a rough-
ly categorized functional interface
Based on the above investigations, especially that of
Step (4), we designed a rough Intermediate Model
as a roughly categorized functional interface between
the two standards. In order to design this starting
model, we took the following four steps. In so doing,
we endeavored to design the structure of the interface
without forcing a change in either model’s concepts.
In other words, we gave priority to matching the con-
ceptual structure of both models as much as possible.(5.1) We deﬁned a pre-Intermediate Model as the
basic framework of the Intermediate Model by
categorizing the object Model into variation d-
ata, direct annotation and indirect annotation,
centering on variation data.
(5.2) Based on results of step (5.1), we restructured
concepts and their relations in the clinical gen-
omics domain.
(5.3) We added those concepts that did not exist in
the pre-Intermediate Model.
(5.4) We adjusted the entire pre-Intermediate Model
using more detailed comparison results to des-
igned the Intermediate Model.Fig. 1. The simpliﬁed structure of the HL7 GeneticLocus Model with
GSVML. Bright red class is the HL7 entry Point. Blue-green class is the
GSVML entry point. The other classes are core classes of the GeneticLo-
cus Model. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this paper.)(6) Development of the Interface Model for a coordinat-
ed functional interface
After the ‘‘to and fro’’ steps of step (5), we were able
to complete the design of our Interface model. These
‘‘to and fro’’ steps were eﬀective in designing a well-
coordinated functional interface.3. Result
3.1. Comparison of the scope
The GeneticLocus Model describes the data relating to a
genetic locus, which CGSIG proposes to be the basic unit
of genomic information exchange in healthcare. It is aimed
at the needs of healthcare with the vision of personalized
medicine in mind. In contrast, although GSVML has the
almost the same purpose, it gives priority to the sequence
variation itself, and is thus aimed at the development of
the most clinically relevant biological model.
3.2. Comparison of entry point
Fig. 1 shows the simpliﬁed structure of the GeneticLo-
cus Model with the GSVML Entry Point, which is a vari-
ation class. In contrast, the entry point of the
GeneticLocus Model is a GeneticLocus class, which could
be associated with a pair of alleles on paternal and mater-
nal homologous chromosomes.
3.3. Comparison of the structure
Fig. 2 shows the outlined structure of GSVML. In
GSVML, variation data and its annotations are hierarchi-
cally categorized, in three criteria, as variation data, direct
annotation, and indirect annotation. The variation data is
associated with genotype, alleles, and sequences in the var-
iation data criterion. The annotations as omics and clinical
concerns are described hierarchically in the direct annota-
tion criterion or the indirect annotation criterion, respec-
tively. Speciﬁcally, the variation data criterion describes
the straightforward variation data as allele, type, position,
length, region, etc. The direct annotation criterion
describes the attached data of variation data as whole
Fig. 2. Outlined structure of GSVML. Green color is GSVML root element. Red color indicates the GSVML three criteria. Yellow color intends variation
data. Blue color indicates direct annotation. Orange color indicates indirect annotation. (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this paper.)
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detect, somatic mutation, experiment analysis, epidemiolo-
gy, and miscellaneous. The indirect annotation criterion
describes the explanatory/higher-level information of vari-
ation data as omics data, clinical information, and environ-
mental data.
Fig. 3 shows the GeneticLocus Model. In the GeneticLo-
cus Model, the main elements are GeneticLocus, Individu-
alAllele, SequenceVariation, Expression, Sequence,
Polypeptide, and ClinicalPhenotype. GeneticLocus is asso-
ciated with the pair of alleles (IndividualAllele). Individu-
alAllele is wrapper element of SequenceVariation,
Expression, and Sequence. SequenceVariation is associated
ClincialPhenotype directly. In addition, each main element
in the GeneticLocus Model also has relation to
ClinicalPhenotype.
Additionally, Figs. 4 and 5 show the GeneticLoci Model
(POCG_RM000050) and the FamilyHistory Model
(POCG_RM000040), respectively. The GeneticLoci
Model allows the representation of data relating to a set
of loci along the DNA material. The set of loci could be
diﬀerent types, such as a haplotype (allele or SNP), a genet-
ic proﬁle, a biological pathway, a set of genetic test results
that contains results of multiple genes, etc. The Genetic-
Loci Model utilizes the GeneticLocus Model as a Common
Message Element Types (CMET), which are intended for
common use across messages produced by all committees.
In the FamilyHistory Model, each family member object is
represented in relation to another family member who
‘‘scopes’’ it. The model utilizes the GeneticLocus Model
in order to capture genomic data in any resolution needed.
It is utilized in this model as one of the choices in the main
ClinicalGenomics choice box, like the ClinicalObservation.3.4. Comparison of the content
Table 1 shows the comparisons of content between
GSVML and the GeneticLocus Model. Table 2 shows a
part of the detailed results of mapping GSVML contents
to the GeneticLocus Model and the other domains of
HL7v3. Both GSVML and the GeneticLocus Model have
the genetic information and the basic information derived
from the genetic information. In the GeneticLocus Model,
the majority of the associated clinical information is
described in the other HL7v3 information models. On the
other hand, GSVML has an ability to describe various
associated information such as experimental conditions,
epidemiology, or statistical information on one model. As
a result, Fig. 6 shows an overview of GSVML contents
in the total HL7v3 contents. Most variation data and a
part of direct annotation information could map to Clini-
cal Genomics Domain in HL7v3. On the other hand, most
indirect annotation and a part of direct annotation, that is
detailed clinical information, could map to other HL7v3
domain. But, Epidemiology and Environment Condition
could hardly map at all to HL7v3.
3.5. Development of the interface model
Fig. 7 shows the Interface Model for interfacing the two
standards. we treated Expression information and Proteo-
mics information in the GeneticLocus Model as subordi-
nate structures of the Indirect Annotation, because it can
be argued that transcriptome and proteome information
are indirect annotations of variation. Since the GeneticLo-
cus Model does not have concept structures such as Envi-
ronmental Condition or Epidemiology (which the
Fig. 3. GeneticLocus Model. This model has HL7v3 artifact identiﬁer ‘‘POCG_RM000010’’.
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the Interface Model. We also added an Associated Gene
class and an Experimental Analysis class in order to better
clarify those concepts. Moreover, PersonalInformation,
Phenotype, OmicsAnnotation, and ClinicalAnnotation in
GSVML were mapped to another domain in HL7v3. In
the Interface Model, we intend to handle that information
through the Phenotype class.
4. Discussion and conclusion
In this study, we analyzed the interface between
GSVML and HL7v3, mainly the GeneticLocus Model in
the Clinical Genomics Domain, as a ﬁrst step towards con-
structing a robust clinical genome infrastructure.
The actual diﬀerences in the scope of the two standards
are fairly subtle. The main focus of the GSVML is on
human health, including clinical practice, preventive medi-
cine, translational research, and clinical research. On the
other hand, the emphasis of the GeneticLocus Model in
the HL7v3 Clinical Genomics Domain is on the personali-
zation of genomic data and the intelligent linking of this
data to relevant clinical information. One reason for this
diﬀerence in focus is that the GeneticLocus Model is
intended to be used as a CMET or Template by any group
using the HL7v3 that needs to convey genomic data.As a result of the diﬀerence in scope, the entry point and
structure of the both models are also diﬀerent. The
GSVML is meant to serve as a biological model, and focus
the application of genetic information, especially variation
information, to human health. Sequence variation is thus
central to its entry point. In contrast, the GeneticLocus
Model is meant to serve more as an informational model.
The GeneticLocus Model is intended to be used by many
contexts (domain) in HL7v3, though of course, the applica-
tion of genetic information to human health is in scope of
it. So, The GeneticLocus Model is genetic Locus centric
and more reusable Model. It is not a question of which
structure is intrinsically better. It is quite natural that the
entry point and the structure of these models are diﬀerent,
since the scope and the context of each model are more or
less diﬀerent. Additionally, all of the HL7v3 models are
based on RIM, a static model derived based on the needs
of the healthcare domain as viewed within the scope of
the HL7 standards development activities. In other words,
representation of the HL7v3 models basically depends on
RIM. Therefore, the GeneticLocus Model in HL7v3 is
more speciﬁc to the healthcare domain.
Regarding contents, the GSVML has both the genetic
information and the associated clinical information within
one model for the application of genome information to
clinical. On the other hand, the GeneticLocus Model uses
Fig. 4. GeneticLoci Model. This model has HL7v3 artifact identiﬁer ‘‘POCG_RM000050’’.
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mation. Thus the GSVML contains not only information,
but also the context, within its model, while it can be said
that the GeneticLocus Model is the reusable, general model
used in the context (story) of other domains.
As a result of these analyses, we developed the Interface
Model. However, not all of the GSVML information cor-
responds to that of HL7v3. Though Environmental Condi-
tion and Epidemiology are important concepts for gene-
based medicine, no detailed description for them exists in
HL7v3. This issue may be resolved by proposing a new sto-
ryboard for the HL7 side.
In order to exchange data with semantic interoperabili-
ty, it is necessary not only to share a common model of the
data representing the domain of interest, but also to use
common sets of terms, that is, a code system drawn from
a terminology and ontology that is fully deﬁned and com-
prehensively represents the concepts in the domain of inter-
est. In HL7v3, the code system has already been
maintained as vocabulary [28]. In addition, there exist
LOINC [29], SNOMED-CT [30], ICD-10 [31], and so on,
as an external clinical code systems. While a code systemfor genetic information has been examined in CGSIG, no
decision has yet been made. On the other hand, the
GSVML does not restrict a detailed code system at the
present stage. Though a detailed analysis of code systems
is beyond the scope of this study, various solutions are pro-
posed to such an interoperability problem [32–35]. Any-
way, Code system will have to be arranged more
appropriately in the future.
Moreover, Ontology exists for a highly ranked concept
of code system. In the ﬁeld of biology, Ontology-based
knowledge representations have been and are being devel-
oped in many domains to facilitate information to support
data interoperability [36–38]. Gene Ontology (GO) [39] has
already been generically used in the genetic ﬁeld. In addi-
tion, other biomedical ontology projects are advanced.
For example, Protein Ontology [40], RNA Ontology [41],
SIGNAL-ONTOLOGY [42] and so on. In the process of
the application of genetic information to clinical, a lot of
omics hierarchies (omics layer) exist. And now, they exist
independently. We think that the integration of such bio-
logical ontology is one of eﬀective approach to treat the
information in omics hierarchy running through and some
Fig. 5. Clinical Genomics Family History Model. This model has HL7v3 artifact identiﬁer ‘‘POCG_RM000040’’.
Table 1
Content comparison of the GSVML with the GeneticLocus Model
GSVML contents GeneticLocus Model
Variation data s
Direct annotation n
Indirect annotation n
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researching this subject.
When we consider the reﬂection of the GSVML in the
EHR, it becomes apparent that CDA is a very important
standard as component of an EHR, since both CDA
Release One and CDA Release Two became an ANSI-ap-
proved HL7 Standard, and also since CDA may become
the main current of the EHR in the future [46,47]. The
model for CDA entries is derived from the shared HL7
Clinical Statement model, which is a collaborative project
between several committees striving to provide a consistent
representation of clinical observations and acts across the
various HL7v3 speciﬁcations. Therefore, it is preferable
that CDA entries either be partially described in terms of
GSVML contents or be preserved in a format that can be
fully integrated with the GSVML contents. On the other
hand, the GeneticLocus Model is intended to be a shared
model, that is CMET, between all domains in HL7v3. So
it is relatively easy to integrate information between eachdomain in HL7v3. we intend to realize the reﬂection of
the GSVML in the EHR by mapping the GSVML contents
to the GeneticLocus Model through the Interface Model
and unifying the mapped GeneticLocus Model and the
CDA.
Realization of gene-based medicine will require an EHR
system with semantic interoperability. Because gene-based
medicine requires detailed individual clinical information
accumulated independently in healthcare facilities, and to
address the EHR interoperability problem, several stan-
dards and technical speciﬁcations other than HL7v3 are
currently under development [48]. In particular, the CEN
standard EN 13606 ‘‘Electronic Healthcare Record Com-
munication’’ (EHRcom) is a comprehensive EHR standard
currently under development at the technical committee on
Health Informatics of the European Committee for Stan-
dardization (CEN/TC 251) [49]. The GSVML is an inde-
pendent standard by itself. Consequently, we also will
need to analyze standards other than HL7 in the future.
In fact, we have already begun the analysis of the interface
with the CEN EN 13606.
Of course, the realization of gene-based medicine will
not occur only by construction of a robust clinical genome
infrastructure. Development of new analytical methods,
implementation of application systems, and other eﬀorts
will also be necessary. Even so, without construction of this
Table 2
Mapping the GSVML contents to the GeneticLocus Model (Excerpt)
No. GSVML HL7v3
Element Name Attribute
Name
Mapping Mapping details
1 gsvml
2 variation_data ﬁ5
3 direct_annotation ﬁ56
4 indirect_annotation ﬁ192
5 gsvmlvariation_data
6 variation_type GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty [/
code@code=‘‘TYPE’’]/value
@code:variation_type
7 location ﬁ11
8 variation_att ﬁ51
9 source ﬁ59
10 variation_dbref ﬁ72
11 gsvml/variation_data/location
12 chromosome_number GeneticLocus/value
@qualiﬁer:chromosome_number
13 position GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/
code@code=‘‘POS’’]/value
@code:position
14 map GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/
code@code=‘‘?MAP’’]/value
@value:map
15 orientation GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/
code@code=‘‘?ORIENT’’]/value
@value:orientation
16 ass_gene ﬁ20
17 location_dbref ﬁ43
18 gsvml/variation_data/location/ass_ge_ne
19 ass_gene_name GeneticLocus/value @displayName:ass_gene_name
20 ass_gene_structure GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/
code@code=‘‘?POSITION.GENOME’’]/value
@code:ass_gene_structure
21 arninoacid_substitution GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/
code@code=‘‘?ASUB’’]/value
@code:arninoacid_substitution
22 codon_substitution GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/
code@code‘‘?CSUB’’]/value
@code:codon_substitution
23 codon_position GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/
code@code=‘‘POS’’]/value
@code:codon_position
24 ass_gene_symbol GeneticLocus/value @transration:ass_gene_symbol
25 ass_gene_alias GeneticLocus/value @transration:ass_gene_alias
26 ass_gene_product GeneticLocus/component1/IndividualAllele/Component2/
Sequence/Polypeptide/value
@code:ass_gene_product
27 ass_gene_evidence_type GeneticLocus/component/AssosiatedObservationy[/
code@code=‘‘?EVD’’]/value
@code:add_gene_evidence_type
28 changed_motif
29 changed_motif_name
30 changed_splice_site
31 splice_variant_number ﬁ33
32 ass_gene_dbref ﬁ35
33 gsvml/variation_data/location/ass_gene/splice_variant_number
34 refSeq_number
35 gsvml/variation_data/
location/ass_gene/
ass_gene_dbref
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Table 2 (continued)
No. GSVML HL7v3
Element Name Attribute
Name
Mapping Mapping details
36 database_name GeneticLocus/value
@codeSystemName:database_name
37 database_id GeneticLocus/value @codeSystem:database_id
38 link_url
39 database_attbt
40 data_id GeneticLocus/value @code:data_id
41 data_attbt GeneticLocus/value @originalText:data_attbt
42 version GeneticLocus/value @codeSystemVersion:version
43 gsvml/variation_data/location/location_dbref
44 database_name GeneticLocus/value
@codeSystemName:database_name
45 database_id GeneticLocus/value @codeSystem:database_id
46 link_url
47 database_attbt
48 data_id GeneticLocus/value @code:data_id
49 data_attbt GeneticLocus/value @originalText:data_attbt
50 version GeneticLocus/value @codeSystemVersion:version
51 gsvml/variation_data/variation_att
52 molecular_type GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty/code
@code:molecular:_type
53 allele GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
54 length GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/
code@code=‘‘LEN’’]/value
@code:length
55 f5sequence GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/
code@code=‘‘?F5’’]/value
@code:f5sequence
56 f3sequence GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/
code@code=‘‘?F3’’]/value
@code:f3sequence
57 validation_status GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/
code@code=‘‘STAT’’]/value
@code:valiation_status
58 success_rate GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/derivationFrom/AssociatedProperty[/code@
code=‘‘?SRATE’’]/value
@code:success_rate
59 gsvml/variation_data/source
60 source_release_date GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/eﬀectiveTime
61 source_modify_date GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/eﬀectiveTime
62 source_rawdata GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
63 source_dbref ﬁ64
64 gsvml/variation_data/source/source_dbref
65 database_name GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
@codeSystemName:database_name
66 database_id GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
@codeSystem:database_id
67 link_url
68 database_attbt
69 data_id GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
@codedata_id
70 data_attbt GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
@originalText:data_attbt
(continued on next page)
K. Hiroi et al. / Journal of Biomedical Informatics 40 (2007) 527–538 535
Table 2 (continued)
No. GSVML HL7v3
Element Name Attribute
Name
Mapping Mapping details
71 version GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
@codeSystemVersion:version
72 gsvml/variation_data/variation_dbref
73 database_name GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
@codeSystemName:database_name
74 databsase_id GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
@codeSystem:database_id
75 link_url
76 database_attbt
77 data_id GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
@code:data_id
78 data_attbt GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
@originalText:data_attbt
79 version GeneticLocus/component1/IndividualAllele/component3/
SequenceVariation/value
@codeSystemVersion:version
Fig. 6. Overview of GSVML contents in the total HL7v3 contents. Each box indicates a concept or domain in both standards. GSVML contents are
divided into the three categories variation data, direct annotation and indirect annotation. On the other hand, HL7 contents are divided into the three
categories ‘‘Administrative Management Domains’’, ‘‘Health and Clinical Management Domains’’ and ‘‘Common Domains’’, and each category contain
speciﬁc domains. This is almost the same classiﬁcation as that of the ‘‘Domains’’ of the HL7v3 Ballot Package. Green color (double line) indicates that the
contents (concepts) of GSVML already have the contents (concepts) of the corresponding speciﬁc domain model in HL7v3. Yellow color (single line)
indicates that the contents (concepts) of GSVML partially have the contents (concepts) of the corresponding speciﬁc domain model in HL7v3. Red color
(dotted line) indicates that the contents (concepts) of GSVML do not have the contents (concepts) of the corresponding speciﬁc domain model in HL7v3.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this paper.)
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be unreliable, and the results of analyzing such data may
be useless. Additionally, for gene-based medicine, statisti-
cal analysis is very important. For example, for what per-
centage (and what types) of patients is a particular
medicine eﬀective? In such analyses, regardless of the statis-
tical method, data quality is vital. More attention should
be paid to this ﬁeld.
A wide variety of data exchange standards exist. In the
bioinformatics ﬁeld alone, there already exist BSML(Bioinformatic Sequence Markup Language) [50], SBML
(Systems Biology Markup Language) [51], CellML (Cell
Markup Language) [52], MAGE-ML (MicroArray and
Gene Expression Markup Language) [53], and so on. How-
ever, the scope of these ‘‘MLs’’ does not include clinical
applications. By contrast, GSVML consists of three data
criteria: variation data, direct annotation, and indirect
annotation. In particular, indirect annotation contains
information such as clinical observation and environmental
condition that are necessary for analyzing multifactorial
Fig. 7. The Interface Model for a coordinated functional interface. Underscored name means the class originates in the GeneticLocus model. Each class is
categorized as variation data, direct annotation, or indirect annotation. Green color means the class categorizes only variation data. Blue color means the
class categorizes both variation data and direct annotation. Purple color means the class categorizes only indirect annotation. Gray color means the class
categorizes only direct annotation. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this
paper.)
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with the variation information also available in GSVML,
integrated analysis for gene-based medicine becomes possi-
ble. Moreover, we expect that medical treatments that are
better than current ones might result if such information
can be related to individual clinical information that cur-
rently is scattered temporally and spatially through the
use of the HL7v3 interface.
We believe that GSVML will, in the future, perform an
important role in gene-based medicine. Nevertheless, it is
important to remember that HL7 is already a central stan-
dard in the healthcare domain. Therefore, by interfacing
GSVML and the HL7v3 GeneticLocus Model, and reﬂec-
tion of GSVML in the EHR, correct data exchange and
data sharing, with interoperability, will be guaranteed.
And the Interface Model we developed in this study will
becomes the basis of such clinical genome infrastructure.
Of course, much implementation work still remains to be
done to achieve this. This study is a ﬁrst, but quite signiﬁ-
cant, step towards this goal. We have already begun collab-
orative activity with HL7v3 CGSIG and the Japanese
Millennium Project [54] to help move the implementation
process forward. We will continue to evaluate and modify
this model, as appropriate, as part of this collaboration.
Recently, a huge amount of data has been collected in
the health care domain, but this data lacks ﬂuidity. In par-
ticular, a high wall separates genomics information and
clinical information. This analysis of the interface between
GSVML and HL7v3 will help break down this wall, there-by enabling the shift of relevant information from the basic
research lab to the clinic, due to the increased interactive
ﬂow of that information. The realization of gene-based
medicine thus can be accelerated.References
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